Primary source: Manage a medical device supply disruption
The TGA executed search warrants resulting in the seizure of illicit peptide and steroid products.
This enforcement action highlights the TGA's commitment to regulating the importation and sale of unapproved therapeutic goods, ensuring consumer safety and compliance with Australian laws.
Regulatory intelligence workflows should address this enforcement action as part of ongoing compliance monitoring regarding the sale and promotion of unapproved therapeutic goods.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Regulatory intelligence workflows should address this enforcement action as part of ongoing compliance monitoring regarding the sale and promotion of unapproved therapeutic goods.
The Therapeutic Goods Administration (TGA) has seized more than $120,000 worth of illicit peptide and anabolic steroid products linked to a social media influencer in New South Wales. This operation, executed on August 4, 2026, included products like retatrutide and CJC-1295, and serves as a warning against unlawful activities involving unapproved therapeutic goods online.
What changed: The TGA executed search warrants resulting in the seizure of illicit peptide and steroid products.
Why it matters: This enforcement action highlights the TGA's commitment to regulating the importation and sale of unapproved therapeutic goods, ensuring consumer safety and compliance with Australian laws.
Practical implication: Regulatory intelligence workflows should address this enforcement action as part of ongoing compliance monitoring regarding the sale and promotion of unapproved therapeutic goods.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
